Michael Palfreyman
Michael Palfreyman
President, Palfreyman BioPharm Advisors
Verified email at
Cited by
Cited by
Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways
CA Altar, P Laeng, LW Jurata, JA Brockman, A Lemire, J Bullard, ...
Journal of Neuroscience 24 (11), 2667-2677, 2004
Simultaneous determination of 3, 4‐dihydroxyphenylalanine, 5‐hydroxytryptophan, dopamine, 4‐hydroxy‐3‐methoxyphenylalanine, norepinephrine, 3, 4‐dihydroxyphenylacetic acid …
J Wagner, P Vitali, MG Palfreyman, M Zraika, S Huot
Journal of neurochemistry 38 (5), 1241-1254, 1982
The role of 5-HT2A receptors in antipsychotic activity
CJ Schmidt, SM Sorensen, JH Kenne, AA Carr, MG Palfreyman
Life sciences 56 (25), 2209-2222, 1995
The relationship between GABA concentrations in brain and cerebrospinal fluid
P Böhlen, S Huot, MG Palfreyman
Brain research 167 (2), 297-305, 1979
NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations
JH Kehne, TC McCloskey, BM Baron, EM Chi, BL Harrison, JP Whitten, ...
European journal of pharmacology 193 (3), 283-292, 1991
Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function
MG Palfreyman, CJ Schmidt, SM Sorensen, MW Dudley, JH Kehne, ...
Psychopharmacology 112 (1), S60-S67, 1993
The pharmacology of GABA-transaminase inhibitors
MG Palfreyman, PJ Schechter, WR Buckett, GP Tell, J Koch-Weser
Biochemical pharmacology 30 (8), 817-824, 1981
Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with …
SH Preskorn, M Gawryl, N Dgetluck, M Palfreyman, LO Bauer, DC Hilt
Journal of Psychiatric Practice® 20 (1), 12-24, 2014
Enzyme-activated irreversible inhibitors of monoamine oxidase: phenylallylamine structure-activity relationships
IA McDonald, JM Lacoste, P Bey, MG Palfreyman, M Zreika
Journal of medicinal chemistry 28 (2), 186-193, 1985
Activity of 5, 7-dichlorokynurenic acid, a potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding site.
BM Baron, BL Harrison, FP Miller, IA McDonald, FG Salituro, CJ Schmidt, ...
Molecular pharmacology 38 (4), 554-561, 1990
Determination of DOPA, dopamine, DOPAC, epinephrine, norepinephrine, α-monofluoromethyldopa and α-difluoromethyldopa in various tissues of mice and rats using reversed-phase …
J Wagner, M Palfreyman, M Zraika
Journal of Chromatography B: Biomedical Sciences and Applications 164 (1), 41-54, 1979
Effect of acute and chronic MDL 73,147 EF, a 5-HT3 receptor antagonist, on A9 and A10 dopamine neurons
SM Sorensen, TM Humphreys, MG Palfreyman
European journal of pharmacology 163 (1), 115-118, 1989
Inhibitors of lysyl oxidase
MG Palfreyman, P Bey, IA McDonald
US Patent 4,965,288, 1990
[3H] 5, 7-Dichlorokynurenic acid, a novel radioligand labels NMDA receptor-associated glycine binding sites
BM Baron, BW Siegel, AL Slone, BL Harrison, MG Palfreyman, SD Hurt
European Journal of Pharmacology: Molecular Pharmacology 206 (2), 149-154, 1991
History of serotonin and serotonin disorders.
A Sjoerdsma, MG Palfreyman
Annals of the New York Academy of Sciences, 1990
Relationship between extracellular 5‐hydroxytryptamine and behaviour following monoamine oxidase inhibition and l‐tryptophan
AJ Sleight, CA Marsden, KF Martin, MG Palfreyman
British journal of pharmacology 93 (2), 303-310, 1988
(E)-. beta.-(Fluoromethylene)-m-tyrosine: a substrate for aromatic L-amino acid decarboxylase liberating an enzyme-activated irreversible inhibitor of monoamine oxidase
IA McDonald, JM Lacoste, P Bey, J Wagner, M Zreika, MG Palfreyman
Journal of the American Chemical Society 106 (11), 3354-3356, 1984
Inhibitors of lysyl oxidase
MG Palfreyman, P Bey, IA McDonald
US Patent 5,021,456, 1991
Inhibition of monoamine synthesis by irreversible blockade of aromatic aminoacid decarboxylase with α-monofluoromethyldopa
MJ Jung, MG Palfreyman, J Wagner, P Bey, G Ribereau-Gayon, M Zraika, ...
Life sciences 24 (11), 1037-1042, 1979
(E)-2-(3, 4-dimethoxyphenyl)-3-fluoroallylamine: a selective, enzyme-activated inhibitor of type B monoamine oxidase
P Bey, J Fozard, JM Lacoste, IA McDonald, M Zreika, MG Palfreyman
Journal of medicinal chemistry 27 (1), 9-10, 1984
The system can't perform the operation now. Try again later.
Articles 1–20